tbuckley/cabot-search huggingface dataset:
Cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastroesophageal cancer (GEC).
Authors: Katrine Rahbek Schoennemann, Mette K. N. Yilmaz, Jon Kroll Bjerregaard, Helle Anita Jensen, Kirsten Marie Nielsen, Lene Weber Vestermark, Per Pfeiffer
Journal: Journal of Clinical Oncology (2012)

101 Background: Inspired by the promising results seen in patients (pts) with chemo-resistant metastatic colorectal cancer we evaluated a biweekly schedule of cetuximab (cet) and irinotecan (iri) (Cetiri) (Pfeiffer et al. Ann Oncol 2008) in platinum resistant GEC. Methods: We treated and evaluated 111 consecutive pts with histological verified GEC adenocarcinoma and documented failure to first-line platinum-based treatment. Pts received cet 500 mg/m 2 and iri 180 mg/m 2 day 1 every 2 nd week until progression or unacceptable toxicity. Toxicity was evaluated according to NCI-CTCAE v. 3.0. Response rate (RR) was evaluated according to RECIST v. 1.0 every 8 th week. Clinical parameters and blood samples at baseline were analyzed in order to find prognostic and predictive values for prolonged overall survival (OS). Results: Pts were included from December 2007 to August 2010. Median age was 61 years (range 33-80). Performance status (PS) was 0-1 in 95 % of the pts. Thirty-six (46%) pts had more than two organs involved. Median number of courses was 8 (1-46). RR was 14% (2 CR, 13 PR) and 63% had stable disease for at least 2 months. Median PFS and OS were 3.2 months (CI 2-4) and 5.6 months (CI: 5-7) respectively. Seventy six (68%) pts had treatment induced skin toxicity, rash. In a univariate analysis PS 0-1, normal baseline haematology and skin rash was associated with significantly increased survival. These parameters retained significance in a multivariate analysis. One patient had a curative resection after end of treatment and four pts are still alive. Conclusions: Biweekly Cetiri is a convenient and well-tolerated second-line (SL) regimen in pts with GEC adenocarcinoma. Good performance status, normal baseline and development of skin rash indicate increased survival. Based on our findings biweekly Cetiri can be recommended as SL treatment to GEC pts in a good PS. Further studies into the role of rash are warranted.
From the Centers for Disease Control. Progress toward achieving the 1990 objectives for the nation for sexually transmitted diseases
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROCTOLOGISTS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.
Authors: A. W. Tolcher, R. D. Baird, A. Patnaik, V. Moreno Garcia, K. P. Papadopoulos, C. R. Garrett, D. Olmos, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith, J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono
Journal: Journal of Clinical Oncology (2011)

3004 Background: The PI3K-Akt and RAF/MEK/ERK pathways represent two of the most frequently activated growth factor signaling pathways in human cancer. Inhibition of both pathways could yield greater benefits than inhibiting either pathway alone. The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib. This investigational study represents a new approach to early-stage drug development with the collaboration of two pharmaceutical companies co-developing early stage targeted agent combinations (NCT01021748). Methods: Eligible patients with advanced solid tumors were treated with MK-2206 either every other day (QOD) or once weekly (QW), in combination with selumetinib administered continuously either once daily (QD) or twice daily (BID). Results: To date, 33 patients have been treated on five dose levels. In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD. For QW MK-2206, dose-limiting acneiform rash (n=1), stomatitis (n=1) and detached retinal pigment epithelium (n=1) were observed in 3/7 evaluable patients treated at MK-2206 90 mg QW with selumetinib 75mg BID; dose reduction to MK-2206 90mg QW/ selumetinib 50 mg BID was not tolerated due to dose-limiting acneiform rash in 2/ 4 evaluable patients. An intermediate dose of MK-2206 90mg once weekly with selumetinib 75mg QD was tolerable. Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination. Conclusions: MK2206 at 45 mg QOD, or 90 mg QW is well tolerated in combination with selumetinib 75 mg QD in patients with advanced cancer.
JAMA Internal Medicine
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Lauren Fischer, John Mcfadden, Donald Smith, Karen Boyd, Rochelle Lodder, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Roya Coerver-Connolly, Laura Khatiblou, Juliann King, Donna Tarsney, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Managers, Staff Gardner- Gullens, Fanny Brown, Paul Frank, Peter Kim, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Kate Pezalla, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Joshua Bird, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy Classified, Thalia Moss, Mike Harvey, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Millie, Lara Marketing, Matt Herron, Elizabeth Solaro, Geoffrey Flick, Paul Gee Managers, Rick Bell, Michael Mcgraw, Sara Nagy, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, J Neff, Sean O'donnell, Sean Ohlson, Phil O'leary, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Jeffrey Tabas, San Francisco, Elsayed Soliman, Winston-Salem North, Carolina Gregory, M Marcus, Nora Goldschlager, California Cme, Rebecca Larson, Deborah Grady, Rosemary Gibson, Virginia Arlington, Mitchell Katz, Los Angeles, Patrick California, David Glidden, John Neuhaus, Kenneth Covinsky, Joseph Ross, New Haven, Raman Khanna, Kathleen Mckibbin, Katherine Gilhooley, Mary Kohut, Howard Bauchner, Rita Redberg, Shannon Brownlee, Tanner Caverly, Ann Arbor, Brandon Combs, Christopher Moriates, Neel Shah, Robert Steinbrook, Connecticut Web, Judyann Bigby, Ezekiel Emanuel, Mark Feinglos, Chi-Yuan Hsu, Kurt Kroenke, Grace Lin, Mary Mcdermott, C Noel, Bairey Merz, Samia California, Robert Phillips, Michael Pignone, Chapel Hill, North Carolina, Judith Prochaska, Kathryn Rexrode, Mary Tinetti, Nicolas Rodondi, Iona Heath
Journal: JAMA Internal Medicine (2014)
Prenatal Choice
Authors: Donna Blumenthal
Journal: JAMA (1990)

<h3>To the Editor.—</h3> "Dr Brown"<sup>1</sup>experienced an emotionally and psychologically devastating event that few individuals can begin to appreciate. Despite the fact that we undergo prenatal testing to identify fetal abnormalities, most of us expect and receive normal results. As a genetic counselor, I know that the moment the news is given is never forgotten. Others have described to me the lack of supportive staff or access to hard information, the burden of the decision to terminate, the chasm between husband and wife, the discovery that old coping strategies are ineffectual, and the feeling of isolation. I also have heard many times what Dr Brown did not state, that the diagnosis itself cannot be shared lest one be judged harshly for terminating pregnancy for too little reason, as if anyone outside the situation has the right to judge. In response to these enormous and unique problems, we have developed
Anesthesiology
Authors: S. H. Ngai, E. M. Papper
Journal: New England Journal of Medicine (1963)

Anesthetic TechnicsChanges in Anesthetic PracticeNo precise data on changes in clinical anesthetic practice are available. However, certain trends appear to be taking place if one can judge by subjects presented at meetings, the contents of papers published in the clinical literature of anesthesiology and the examination of statistical reports. These appear to fall into several categories. The trend toward the use of more general anesthesia than regional anesthesia appears to be continuing. The administration of muscle relaxants and controlled respiration during general anesthesia is now so commonplace as to be considered almost routine in many clinics. There also . . .
Isotope-tagged platelets used to locate thrombi
Authors: W. A. Check
Journal: JAMA (1982)

Visualization of platelet aggregates in aneurysms and atherosclerotic arteries is now possible using autologous platelets labeled with the radioactive isotope indium 111. These thrombi can throw off emboli that cause severe vascular damage in the lungs, brain, or limbs and that are "one of the primary causes of acute morbidity and death in the Western world," according to Michael D. Ezekowitz, MD, cardiologist at the University of Oklahoma Health Sciences Center in Oklahoma City. At the recent Joint Conference on Stroke and Cerebral Circulation in New Orleans, three research groups, including that of Ezekowitz, discussed their findings with the radioisotope method. They agreed that it is accurate in some circumstances but needs further refinement before it becomes clinically useful on a routine basis. The same applies to another, similar use of the<sup>111</sup>In labeling technique—that of labeling autologous WBCs that are then reinfused into the patient and serve to
MUSCLE INJURY RATES IN PROFESSIONAL FOOTBALL INCREASE WITH FIXTURE CONGESTION: AN 11-YEAR FOLLOW-UP OF THE UEFA CHAMPIONS LEAGUE INJURY STUDY
Authors: H Bengtsson, J Ekstrand, M Waldén, M Hägglund
Journal: British Journal of Sports Medicine (2014)

Background The influence of fixture congestion on injury rates and team performance has only been scarcely investigated. Objective To study associations between match load, recovery days, injury rates and team match performances in professional football. Design Prospective cohort study. Setting European professional football. Participants 27 teams, all selected by the UEFA and all competing at the highest level of European football, playing 8 150 competitive matches during the 11-year study period were included. Assessment of risk factors Injury rates and team match performances were compared depending on the number of recovery days between matches using two different cut offs (≤3 vs. &gt;3 days and ≤4 vs. ≥6 days). Match load, injury rates and team match performances were also studied over extended match sequences during the season, each sequence containing five consecutive matches over a mean of 27 days (range 7–104 days). Main outcome measurements Number of time loss injuries/1000 h of exposure and amount of matches won, lost or drawn. Results Team performance showed no association with match load except for Europa League matches that indicated more matches lost with ≤3 days compared with &gt;3 days recovery (P=.048). Total injury rates and muscle injury rates, specifically hamstring and quadriceps injuries, were increased in league matches with ≤4 days compared with ≥6 days recovery preceding the match (rate ratio [RR] 1.09, 95% CI 1.00–1.18, and RR 1.32, 95% CI 1.15–1.51, respectively) while no differences were found when using the other cut off (≤3 vs. &gt;3 days). High match load during a match sequence was associated with an increase in muscle injury rates (P=.012). Conclusions Fixture congestion was associated with increased muscle injury rates but had no, or very limited, influence on team match performances.
Incorrect Impact Areas.
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the Advisory ACIP Committee for Elimination of Tuberculosis
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Deaths Attributed to Nor'easter—December 1992
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Handbook of Midwifery
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SHORT TEXTBOOKS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterization of alterations in mechanical, thermal and pain sensitivity in cirrhotic patients with minimal hepatic encephalopathy
Authors: Dalia Rega, Mika Aiko, Nicolás Peñaranda, Juan José Gallego, Andrea Cabrera-Pastor, Amparo Urios, Franc Casanova, Alessandra Fiorillo, Carla Gimenez, Cristina Ipiens, Desamparados Escudero-García, Joan Tosca, Cristina Montón, María Pilar Ballester, Jose Ballester, Vicente Roig, María Pilar Rios, Lucía Durbán, Paula Cases, Vicente Felipo, Carmina Montoliu
Journal: Journal of Hepatology (2020)
Mount Misery
Authors: Steven S. Sharfstein
Journal: JAMA (1997)

Since 1988 there has been nearly a 40% decline in the number of US medical school seniors entering psychiatry. This decrease, from 745 in 1988 to 462 in 1997, is the result of the uncertain medical marketplace, with psychiatry being particularly vulnerable to managed caredriven change. How much this decline is due to competing ideological schools of psychiatry and problems within the specialty itself is a subject of debate. <i>Mount Misery</i>by Samuel Shem (a pseudonym for Dr Stephen Bergman, a psychiatrist) is the long-awaited sequel to<i>The House of God</i>and could lead to an even more precipitous decline in the medical specialty if it is as widely read as its predecessor. This novel takes the same hero, Dr Roy Basch, through his first year of psychiatric residency at Mount Misery, an apocryphal private psychiatric hospital near Boston. Hoping to find his identity as a healing physician in psychiatry